473 related articles for article (PubMed ID: 24898559)
1. Effect of dutasteride 0.5 mg/d in men with androgenetic alopecia recalcitrant to finasteride.
Jung JY; Yeon JH; Choi JW; Kwon SH; Kim BJ; Youn SW; Park KC; Huh CH
Int J Dermatol; 2014 Nov; 53(11):1351-7. PubMed ID: 24898559
[TBL] [Abstract][Full Text] [Related]
2. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia.
Gubelin Harcha W; Barboza Martínez J; Tsai TF; Katsuoka K; Kawashima M; Tsuboi R; Barnes A; Ferron-Brady G; Chetty D
J Am Acad Dermatol; 2014 Mar; 70(3):489-498.e3. PubMed ID: 24411083
[TBL] [Abstract][Full Text] [Related]
3. The efficacy and safety of 5α-reductase inhibitors in androgenetic alopecia: a network meta-analysis and benefit-risk assessment of finasteride and dutasteride.
Gupta AK; Charrette A
J Dermatolog Treat; 2014 Apr; 25(2):156-61. PubMed ID: 23768246
[TBL] [Abstract][Full Text] [Related]
4. Superiority of dutasteride over finasteride in hair regrowth and reversal of miniaturization in men with androgenetic alopecia: A randomized controlled open-label, evaluator-blinded study.
Shanshanwal SJ; Dhurat RS
Indian J Dermatol Venereol Leprol; 2017; 83(1):47-54. PubMed ID: 27549867
[TBL] [Abstract][Full Text] [Related]
5. Dutasteride in Androgenetic Alopecia: An Update.
Arif T; Dorjay K; Adil M; Sami M
Curr Clin Pharmacol; 2017; 12(1):31-35. PubMed ID: 28294070
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of efficacy and safety of finasteride 1 mg in 3177 Japanese men with androgenetic alopecia.
Sato A; Takeda A
J Dermatol; 2012 Jan; 39(1):27-32. PubMed ID: 21980923
[TBL] [Abstract][Full Text] [Related]
7. The effectiveness of finasteride and dutasteride used for 3 years in women with androgenetic alopecia.
Boersma IH; Oranje AP; Grimalt R; Iorizzo M; Piraccini BM; Verdonschot EH
Indian J Dermatol Venereol Leprol; 2014; 80(6):521-5. PubMed ID: 25382509
[TBL] [Abstract][Full Text] [Related]
8. Androgenetic alopecia; drug safety and therapeutic strategies.
Motofei IG; Rowland DL; Baconi DL; Tampa M; Sârbu MI; Păunică S; Constantin VD; Bălălău C; Păunică I; Georgescu SR
Expert Opin Drug Saf; 2018 Apr; 17(4):407-412. PubMed ID: 29363345
[TBL] [Abstract][Full Text] [Related]
9. The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride.
Olsen EA; Hordinsky M; Whiting D; Stough D; Hobbs S; Ellis ML; Wilson T; Rittmaster RS;
J Am Acad Dermatol; 2006 Dec; 55(6):1014-23. PubMed ID: 17110217
[TBL] [Abstract][Full Text] [Related]
10. Effective treatment of female androgenic alopecia with dutasteride.
Olszewska M; Rudnicka L
J Drugs Dermatol; 2005; 4(5):637-40. PubMed ID: 16167423
[TBL] [Abstract][Full Text] [Related]
11. Combination therapy with finasteride and low-dose dutasteride in the treatment of androgenetic alopecia.
Boyapati A; Sinclair R
Australas J Dermatol; 2013 Feb; 54(1):49-51. PubMed ID: 22686691
[TBL] [Abstract][Full Text] [Related]
12. Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS).
Nickel JC; Gilling P; Tammela TL; Morrill B; Wilson TH; Rittmaster RS
BJU Int; 2011 Aug; 108(3):388-94. PubMed ID: 21631695
[TBL] [Abstract][Full Text] [Related]
13. Changes in hair weight and hair count in men with androgenetic alopecia after treatment with finasteride, 1 mg, daily.
Price VH; Menefee E; Sanchez M; Ruane P; Kaufman KD
J Am Acad Dermatol; 2002 Apr; 46(4):517-23. PubMed ID: 11907500
[TBL] [Abstract][Full Text] [Related]
14. A 5-year retrospective analysis of 5α-reductase inhibitors in men with benign prostatic hyperplasia: finasteride has comparable urinary symptom efficacy and prostate volume reduction, but less sexual side effects and breast complications than dutasteride.
Kaplan SA; Chung DE; Lee RK; Scofield S; Te AE
Int J Clin Pract; 2012 Nov; 66(11):1052-5. PubMed ID: 23067029
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of long-term efficacy of finasteride in Korean men with androgenetic alopecia using the basic and specific classification system.
Shin JW; Chung EH; Kim MB; Kim TO; Kim WI; Huh CH
J Dermatol; 2019 Feb; 46(2):139-143. PubMed ID: 30536893
[TBL] [Abstract][Full Text] [Related]
16. A randomized, double-blind controlled study of the efficacy and safety of topical solution of 0.25% finasteride admixed with 3% minoxidil vs. 3% minoxidil solution in the treatment of male androgenetic alopecia.
Suchonwanit P; Srisuwanwattana P; Chalermroj N; Khunkhet S
J Eur Acad Dermatol Venereol; 2018 Dec; 32(12):2257-2263. PubMed ID: 29972712
[TBL] [Abstract][Full Text] [Related]
17. The efficacy and safety of dutasteride compared with finasteride in treating men with androgenetic alopecia: a systematic review and meta-analysis.
Zhou Z; Song S; Gao Z; Wu J; Ma J; Cui Y
Clin Interv Aging; 2019; 14():399-406. PubMed ID: 30863034
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic experience with oral finasteride for androgenetic alopecia in female-to-male transgender patients.
Moreno-Arrones OM; Becerra A; Vano-Galvan S
Clin Exp Dermatol; 2017 Oct; 42(7):743-748. PubMed ID: 28691187
[TBL] [Abstract][Full Text] [Related]
19. Comparison of oral minoxidil, finasteride, and dutasteride for treating androgenetic alopecia.
Gupta AK; Talukder M; Williams G
J Dermatolog Treat; 2022 Nov; 33(7):2946-2962. PubMed ID: 35920739
[TBL] [Abstract][Full Text] [Related]
20. Adverse Sexual Effects of Treatment with Finasteride or Dutasteride for Male Androgenetic Alopecia: A Systematic Review and Meta-analysis.
Lee S; Lee YB; Choe SJ; Lee WS
Acta Derm Venereol; 2019 Jan; 99(1):12-17. PubMed ID: 30206635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
